Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.
View Full Profile
At this year's SAN Antonio breast cancer symposium, we will be sharing the results of a recently completed clinical trial which focused on new treatment combinations for patients with metastatic breast cancer to the brain that is called her two positive. This was a multi center study in collaboration with the translational breast cancer Research consortium. In three separate cohorts of patients, 44 patients in total who had her two positive brain metastases. All patients received the combination of a treatment called T. D. M. One and a second treatment called Nurettin IB. Regardless of whether a patient had never been treated for their brain metastases or who had received prior treatments including T The M1, the treatment combination resulted in a response rate of approximately 29-33% across the cohorts, meaning there was a significant reduction in brain tumors. For these patients are results for those who had received prior TDM one were unexpected and hypothesis driving because patients could be re challenge with this agent along with narrative and still benefit.
